Sole Representative from the Pharmaceutical Industry
BEIJING–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that James Xue, PhD, CANbridge Founder, Chairman and CEO, was named one of six Deputy Director Generals at the Second General Election Meeting of the Shanghai Foundation for Rare Disease, in Shanghai, China on December 21st. He is the first and only industry representative appointed to such a position in the organization.
The Shanghai Foundation for Rare Disease is the first foundation that is dedicated to rare disease advocacy in mainland China. Within China, Shanghai is a leader in rare disease diagnosis and treatment and home to several world-class rare disease medical facilities.
“It is a great honor to be appointed to this leadership position at the Shanghai Foundation for Rare Disease, particularly as the first pharmaceutical industry representative on the leadership team, which underscores the vital role we play in advancing the care of rare diseases,” said James Xue, PhD, Founder, Chairman and CEO, CANbridge Pharmaceuticals. “I look forward to working with other stakeholders to advance awareness of, and treatment for, rare diseases in China, particularly in the areas of early diagnosis and access to treatment, as well as local policy measures to foster a sustainable rare disease ecosystem.”
About the Shanghai Foundation for Rare Disease
The Shanghai Foundation for Rare Disease is a non-profit organization focused on raising awareness for rare diseases and support for the patients affected by them. Founded in 2014, it was the first regional foundation for rare diseases in mainland China.
The Foundation aims to foster exchange and communications between rare disease experts and scholars, patient advocacy groups, non-profit organizations, the pharmaceutical industry, government and other relevant parties. The Foundation also seeks to promote innovative scientific research; improve accessibility of rare disease drugs; advocate for related policies; initiate international meetings and activities and advance rare disease treatment development in China.
Since its founding, the Foundation has provided comprehensive medical staff training, as well as patient aid and services and enhanced rare disease awareness. It has also initiated patient registration; organized multi-disciplinary discussions among key stakeholders; advocated for rare disease legislation and drafted rare disease regulations.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a China-based biopharmaceutical company accelerating development and commercialization of specialty healthcare products for orphan diseases and targeted cancers, focusing on products that are unavailable or address medical needs that are underserved in the region.
CANbridge has been widely recognized as a leader in orphan diseases in China. It has a global partnership with WuXi Biologics to develop and commercialize proprietary therapeutics for the treatment of rare genetic diseases. In addition, it has an exclusive licensing agreement to commercialize Hunterase®, an enzyme replacement therapy for the treatment of Hunter syndrome, developed by GC Pharma and marketed in more than ten countries worldwide. CANbridge also has an oncology portfolio, which includes exclusive rights to develop and commercialize Puma Biotechnology’s NERLYNX® (neratinib), approved in the US, and rights to other novel candidates.
For more on CANbridge Pharmaceuticals Inc., please go to www.canbridgepharma.com
CANbridge Pharmaceutical Inc.